Welcome to our dedicated page for Predictive Oncology SEC filings (Ticker: POAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Predictive Oncology’s SEC disclosures can feel like running a clinical trial of your own—hundreds of pages on AI-driven drug screens, biobank valuations, and FDA-regulated devices. Whether you’re tracking STREAMWAY revenue or the PEDAL platform’s impact on R&D spend, the details hide deep inside 10-K footnotes and 8-K exhibits.
Stock Titan solves that problem. Our AI-powered summaries translate each Predictive Oncology annual report 10-K simplified, every quarterly earnings report 10-Q filing, and each Predictive Oncology 8-K material events explained into clear, actionable language. Need real-time alerts? We surface Predictive Oncology Form 4 insider transactions in real time, flagging executive stock sales before they hit the news. The platform covers the full spectrum—proxy statement executive compensation tables, registration statements, and even niche S-8 filings—updated the minute EDGAR posts.
Looking for specific answers? Use our search prompts like “understanding Predictive Oncology SEC documents with AI” or “Predictive Oncology earnings report filing analysis” and jump straight to AI-generated highlights: segment revenue trends, cash runway projections, and risk-factor changes. Monitor Predictive Oncology insider trading Form 4 transactions, compare R&D outlays quarter-over-quarter, or download clean tables for your own models. With comprehensive filing coverage, plain-English explanations, and machine-learning insights, Stock Titan turns complex biotech disclosures into practical intelligence investors actually use.
Predictive Oncology Inc. (POAI) reporting person Raymond F. Vennare, who serves as Chief Executive Officer and a director, received a grant of 124,959 restricted stock units (RSUs) on 09/09/2025. Each RSU converts to one share of common stock upon vesting. The RSUs are scheduled to vest in full on October 31, 2025, subject to continued service through that date. Following the grant, the reporting person beneficially owns 132,081 shares of common stock as of the reported transaction. The Form 4 was signed on 09/11/2025 by an attorney-in-fact.
Joshua Blacher, identified as Interim CFO and an officer of Predictive Oncology Inc. (POAI), filed an initial Form 3 disclosing that he does not beneficially own any securities of the issuer. The report lists the relevant event date as 10/01/2023 and includes a signed remark that the Form 3 is being filed late due to an inadvertent administrative oversight; the filer states he is submitting the form promptly upon discovery and intends to comply with future Section 16(a) filing requirements. No non-derivative or derivative holdings are reported on this form.
Predictive Oncology applies AI and a proprietary biobank of 150,000+ tumor samples to support oncology drug discovery and now operates as a single segment focused on AI-driven cancer-therapy development after reclassifying its Birmingham and Eagan businesses to discontinued operations.
The company reported total assets of $3.44M and total liabilities of $5.09M as of June 30, 2025, producing a stockholders' deficit of $(1.65M). Cash and cash equivalents were $506,078. For the six months ended June 30, 2025 the company recorded revenue of $112,992, a net loss of $4.51M (continuing operations loss of $4.26M), and net cash used in continuing operating activities of $4.28M. The company sold its Eagan assets for $625,000 (plus assumed liabilities) and closed related discontinued operations.
Management discloses substantial doubt about the company’s ability to continue as a going concern without additional financing. Nasdaq notified the company of noncompliance but a Hearings Panel granted an extension through December 8, 2025. Subsequent events include a standby equity purchase agreement providing the right to sell up to $10.0M of common stock subject to conditions and a proposed 1-for-15 reverse stock split subject to stockholder approval.
Predictive Oncology (POAI) has scheduled a 2025 Special Meeting to vote on three board-backed items:
- Reverse Stock Split 1-for-15 – designed to lift the share price above Nasdaq’s US$1.00 minimum and remedy bid-price and equity deficiencies. Nasdaq has granted an extension until 8 Dec 2025.
- Nasdaq Proposal – authorize issuance of up to US$10 million in common stock under a Standby Equity Purchase Agreement (SEPA) with YA II PN, Ltd. Yorkville can purchase shares over 36 months at VWAP minus 4 %, potentially exceeding the 19.99 % “Exchange Cap.”
- Adjournment Proposal – permits the meeting to be postponed to secure sufficient votes.
The reverse split will consolidate every 15 shares into one, reduce the shares outstanding accordingly and round up fractional entitlements. While the move should improve marketability and preserve the Nasdaq listing, it increases the pool of authorized but unissued shares, raising dilution and anti-takeover concerns. The SEPA offers flexible working-capital financing, yet further share sales will dilute existing holders and depend on shareholder approval to lift the cap.
Failure to pass Proposals 1 or 2 risks delisting and limits access to the full SEPA facility. The board unanimously recommends voting FOR all three proposals.
FAQ
What is the current stock price of Predictive Oncology (POAI)?
What is the market cap of Predictive Oncology (POAI)?
